文献速递类风湿关节炎

活化蛋白C靶向免疫细胞与类风湿滑膜成纤维细胞预防小鼠炎症性关节炎

Activated protein C targets immune cells and rheumatoid synovial fibroblasts to prevent inflammatory arthritis in mice.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

该研究探讨生理性抗凝蛋白活化蛋白C(APC)在体外抑制免疫细胞和类风湿关节炎滑膜成纤维细胞(RASFs)炎症/侵袭特性,并在小鼠抗原诱导性关节炎(AIA)和胶原诱导性关节炎(CIA)模型中预防炎症性关节炎。结果表明APC通过抑制炎症、Th1/Th17表型和RASF侵袭来阻止关节炎发生发展,该作用可能由内皮蛋白C受体介导。

要点

  • APC在体外抑制RASFs产生IL-1β、IL-17和TNF-α及IL-17刺激的增殖和侵袭。
  • APC在体内抑制CIA和AIA模型的血管翳形成、软骨破坏及关节炎发生率/严重度。
  • 阻断内皮蛋白C受体可消除APC在AIA中的早期或预防性作用。

核心结论

  • APC通过抑制炎症、Th1/Th17表型和RASF侵袭来预防CIA和AIA模型的关节炎发生发展,可能由内皮蛋白C受体介导。

研究设计与样本

  • 体外使用RA患者滑膜组织来源的RASFs、人外周血单个核细胞(PBMCs)和小鼠胸腺细胞。
  • 体内在AIA和CIA小鼠模型中评估APC效果。

主要发现

  • APC抑制RASFs中IL-1β、IL-17和TNF-α产生及IL-17刺激的细胞增殖和侵袭。
  • APC抑制小鼠胸腺细胞和人PBMCs中的Th1和Th17表型。
  • APC在CIA和AIA模型中抑制血管翳形成、软骨破坏及关节炎发生率/严重度。
  • 在CIA中,APC治疗显著降低血清IL-1β、IL-6、IL-17、TNF-α和可溶性内皮蛋白C受体水平。

临床怎么用

  • APC可能作为通过抑制炎症和RASF侵袭来预防炎症性关节炎的潜在策略。
  • 内皮蛋白C受体可能是APC发挥预防作用的介导靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate whether activated protein C (APC), a physiological anticoagulant can inhibit the inflammatory/invasive properties of immune cells and rheumatoid arthritis synovial fibroblasts (RASFs) in vitro and prevent inflammatory arthritis in murine antigen-induced arthritis (AIA) and CIA models. METHODS: RASFs isolated from synovial tissues of patients with RA, human peripheral blood mononuclear cells (PBMCs) and mouse thymus cells were treated with APC or TNF-α/IL-17 and the following assays were performed: RASF proliferation and invasion by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and cell invasion assays, respectively; cytokines and signalling molecules using ELISA or western blot; Th1 and Th17 phenotypes in human PBMCs or mouse thymus cells by flow cytometry. The in vivo effect of APC was evaluated in AIA and CIA models. RESULTS: In vitro, APC inhibited IL-1β, IL-17 and TNF-α production, IL-17-stimulated cell proliferation and invasion and p21 and nuclear factor κB activation in RASFs. In mouse thymus cells and human PBMCs, APC suppressed Th1 and Th17 phenotypes. In vivo, APC inhibited pannus formation, cartilage destruction and arthritis incidence/severity in both CIA and AIA models. In CIA, serum levels of IL-1β, IL-6, IL-17, TNF-α and soluble endothelial protein C receptor were significantly reduced by APC treatment. Blocking endothelial protein C receptor, the specific receptor for APC, abolished the early or preventative effect of APC in AIA. CONCLUSION: APC prevents the onset and development of arthritis in CIA and AIA models via suppressing inflammation, Th1/Th17 phenotypes and RASF invasion, which is likely mediated via endothelial protein C receptor.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Xue M, Dervish S, McKelvey KJ, et al. Activated protein C targets immune cells and rheumatoid synovial fibroblasts to prevent inflammatory arthritis in mice. Rheumatology (Oxford). 2019. PMID: 30649471. doi:10.1093/rheumatology/key429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。